ArticleJournal of ginseng research2024
Effects of Korean Red Ginseng combination therapy on HIV-infected patients treated with integrase strand transfer inhibitors.
Article in Journal of ginseng research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Korean red ginseng on the HIV-1Journal of ginseng research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Korean Red Ginseng (KRG) combined with antiretroviral therapy (ART) has shown benefits in the treatment of HIV-1-infected patients. Current guidelines recommend regimens containing integrase strand transfer inhibitors (INSTIs) as first-line treatment for these patients. The present study assessed the duration of effectiveness of ginseng combination therapy (GCT) in patients receiving INSTIs. Methods: This study included 58 HIV-1-infected patients previously untreated with monotherapy or two-drug combination therapy. Patients in the GCT (n = 26) group received ART plus KRG for 164 ± 64 months, whereas patients in the control (n = 32) group received ART alone for 128 ± 49 months. Subsequently, patients in these two groups received INSTI for 81 ± 36 months and 68 ± 26 months, respectively. Results: Before INSTI treatment, only one drug resistance mutation (DRM) was observed in the GCT group, compared with an overall resistance rate of 44.4 % in the control group (P < 0.001). The overall resistance rate was higher in the control than in the GCT group (9.5 % vs. 0.12 %, P < 0.001). During INSTI treatment, the resistance rate in the GCT group remained 0 % for over 5 years, but gradually decreased in the control group from 18.3 % to 13.9 % over 6 years, indicating that the between-group difference in resistance rate gradually decreased during INSTI treatment. Conclusion: The beneficial effects of KRG were well maintained for more than 20 years, including the INSTI treatment period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.